Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated due to portfolio re-prioritization and strategic considerations. The decision was not based on any safety concerns and/or regulatory interactions

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Sasanlimab Prefilled syringe
DRUG: Encorafenib
DRUG: Binimetinib
DRUG: Sasanlimab
DRUG: Axitinib
DRUG: SEA-TGT

Sponsor

Pfizer